Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma

Open-angle Glaucoma Clinical Trial

— MEMO-GCAO  

Official title:

Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04499157
• Other study ID #: PI2019_843_0061
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2020
• Est. completion date: August 2023

Study information

• Verified date: February 2023
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: Claire Iscar, MD
• Phone: (33)322089200
• Email: Iscar.claire[@]chu-amiens.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open-angle glaucoma is a degeneration of the optic nerve, highlighted by campimetric alterations, and wose only current therapeutic target is the lowering of the intra-ocular pressure (using eye drops, surgery or laser). MEMOPTIC is a tablet combining citicoline, magnesium and Gingko biloba, which have a neuroprotective effect already used in neurodegenerative diseases such as Alzheimer's disease for example. Citicoline has also shown several promising results in ophthalmological diseases (glaucoma, amblyopia or more recently in ischemic optic neuropathies). The citicoline used in eye drops (NEURODROP) has already shown results on the preservation of the vision of glaucomatous patients.

The purpose of this project is to determine if MEMOPTIC can have an effect, in addition to the conventional treatments, in the preservation of vision of patients treated for an open-angle glaucoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: August 2023
• Est. primary completion date: August 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• diagnosis of GCAO defined by OCT RNFL alterations and visual fields defects

• age between 20 and 80 years old

• Well controled intra-ocular pressure under treatment (PIO<21mmHg or decreased by 20% compared to initial the PIO)

Exclusion Criteria:

• retinal or macular disease

• diagnosis of cataract or surgery of cataract during the follow-up

• allergy to citicolin

• ocular hypertonia due to a secondary cause (like corticosteroids)

• history of anterior, intermediate or posterior uveitis

• general treatment affecting PIO (beta blockers, corticosteroids)

• pregnancy or breastfeeding

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle
• Open-angle Glaucoma
• Visual Field

Intervention

Drug:
• MEMOPTIC
Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
• usual treatment of glaucoma
Patients will receive only their usual treatment of glaucoma.

Locations

Country	Name	City	State
France	CHU Amiens	Amiens

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Variation of visual field of open angle-glaucoma patients with MEMOPTIC treatment	Variation of visual field of open angle-glaucoma patients with MEMOPTIC treatment versus visual field of open angle-glaucoma patients without MEMOPTIC treatment. Visual field is measure with METROVISION Visual Field 24-2, a full field projection perimeter entirely compatible with the Goldmann standard and modern perimetry standard. It allows high resolution static perimetry as well as kinetic perimetry with automated and manual modes. Automated static perimetry is one of the methods used to screen and follow up patients who have glaucoma. It consists of approximately 100 quantitative threshold measures that permit evaluation of retinal sensitivity. Each measure is standardized in a population free of ocular disease, and two simple statistics are calculated: mean deviation (MD) and pattern standard deviation (PSD). These indices are widely used in glaucoma clinical trials and patient follow-up.	from day 0 to 2 years